FI965153A - Metalloproteinaasi-inhibiittorit - Google Patents

Metalloproteinaasi-inhibiittorit Download PDF

Info

Publication number
FI965153A
FI965153A FI965153A FI965153A FI965153A FI 965153 A FI965153 A FI 965153A FI 965153 A FI965153 A FI 965153A FI 965153 A FI965153 A FI 965153A FI 965153 A FI965153 A FI 965153A
Authority
FI
Finland
Prior art keywords
compounds
metalloproteinase
inhibitors
medicine
processes
Prior art date
Application number
FI965153A
Other languages
English (en)
Swedish (sv)
Other versions
FI965153A0 (fi
Inventor
Andrew Miller
Mark Whittaker
Raymond Paul Beckett
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9412514A external-priority patent/GB9412514D0/en
Priority claimed from GBGB9506107.3A external-priority patent/GB9506107D0/en
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Publication of FI965153A publication Critical patent/FI965153A/fi
Publication of FI965153A0 publication Critical patent/FI965153A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
FI965153A 1994-06-22 1996-12-20 Metalloproteinaasi-inhibiittorit FI965153A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9412514A GB9412514D0 (en) 1994-06-22 1994-06-22 Metalloproteinase inhibitors
GBGB9506107.3A GB9506107D0 (en) 1995-03-24 1995-03-24 Metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
FI965153A true FI965153A (fi) 1996-12-20
FI965153A0 FI965153A0 (fi) 1996-12-20

Family

ID=26305102

Family Applications (1)

Application Number Title Priority Date Filing Date
FI965153A FI965153A0 (fi) 1994-06-22 1996-12-20 Metalloproteinaasi-inhibiittorit

Country Status (17)

Country Link
US (4) US5962529A (fi)
EP (2) EP0766664B1 (fi)
JP (2) JPH10507158A (fi)
CN (1) CN1151157A (fi)
AT (2) ATE191468T1 (fi)
AU (2) AU695507B2 (fi)
CA (2) CA2193691A1 (fi)
DE (2) DE69516143T2 (fi)
DK (2) DK0766664T3 (fi)
ES (2) ES2145913T3 (fi)
FI (1) FI965153A0 (fi)
GB (2) GB2303850B (fi)
GR (2) GR3031143T3 (fi)
NO (1) NO965515L (fi)
NZ (2) NZ288298A (fi)
PT (1) PT766664E (fi)
WO (2) WO1995035276A1 (fi)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US6380366B1 (en) * 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
GB2303850B (en) * 1994-06-22 1998-06-10 British Biotech Pharm Metalloproteinase inhibitors
US5817822A (en) * 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
ATE226936T1 (de) * 1995-08-08 2002-11-15 Ono Pharmaceutical Co Hydroxamsäurederivate verwendbar zur hemmung von gelatinase
DK0861236T4 (da) † 1995-11-13 2006-12-18 Sanofi Aventis Deutschland Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US6153757A (en) * 1995-12-08 2000-11-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors and intermediates useful for their preparation
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
CA2242416C (en) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
ATE359264T1 (de) 1996-01-23 2007-05-15 Shionogi & Co Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20000011095A (ko) * 1996-05-17 2000-02-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 비페닐술폰아미드 매트릭스 메탈로프로테이나아제 억제제
ES2231879T3 (es) * 1996-08-16 2005-05-16 Warner-Lambert Company Llc Inhibidores de metaloproteinasas de la matriz de acido butirico.
IL128189A0 (en) * 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
KR20000035925A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 매트릭스 메탈로프로테아제 저해제인 포스핀산 아미드
CA2264045A1 (en) * 1996-08-28 1998-03-05 Randall Stryker Matthews Heterocyclic metalloprotease inhibitors
CN1228772A (zh) 1996-08-28 1999-09-15 普罗克特和甘保尔公司 杂环金属蛋白酶抑制剂
ATE272062T1 (de) * 1996-08-28 2004-08-15 Procter & Gamble Spirocyclisch metalloprotease inhibitoren
KR20000035918A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,3-디헤테로시클릭 메탈로프로테아제 저해제
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
IL129147A0 (en) * 1996-10-16 2000-02-17 American Cyanamid Co The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
ES2171905T3 (es) * 1996-10-22 2002-09-16 Upjohn Co Acidos alfa-amino sulfonilo hidroxamicos como inhibidores de metaloproteinasa de matriz.
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
AU5426398A (en) 1996-10-28 1998-05-22 Versicor Inc Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
CN1243507A (zh) * 1997-01-17 2000-02-02 法玛西雅厄普约翰美国公司 用作mmp抑制剂的双磺酰胺异羟肟酸类化合物
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6197791B1 (en) 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
EP0983267B1 (en) 1997-03-04 2005-01-26 Pharmacia Corporation Amidoaromatic ring sulfonamide hydroxamic acid compounds
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EP0973748A1 (en) * 1997-04-01 2000-01-26 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
DK0877019T3 (da) 1997-05-09 2002-04-08 Hoechst Ag Substituerede diaminocarboxylsyrer
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
US6300514B1 (en) 1997-06-25 2001-10-09 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
US6423729B1 (en) 1997-07-22 2002-07-23 Shionogi & Co., Ltd. Therapeutic or prophylactic agent for glomerulopathy
JP2001513484A (ja) 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー 非環式メタロプロテアーゼ阻害剤
DE69805473T2 (de) * 1997-08-08 2003-01-16 Pfizer Prod Inc Arylsulfonylaminohydroxamsäurederivate
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
GB9801690D0 (en) * 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
HUP0101176A3 (en) 1998-02-04 2002-06-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
ID25639A (id) * 1998-02-19 2000-10-19 American Cyanamid Co Alkil, aril atau heteroarilamida tersubstitusi n-hidroksi-2-(alkil, aril, atau heteroaril sulfanil, sulfinil atau sulfonil)-3 sebagai inhibitor matriks mataloproteinase
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
DE59903329D1 (en) 1998-07-16 2002-12-12 Aventis Pharma Gmbh Phosphin- und phosphonsäurederivate als arzneimittel
US6107337A (en) * 1998-08-06 2000-08-22 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6506936B1 (en) * 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
BR0009244A (pt) 1999-03-03 2002-04-16 Procter & Gamble Inibidores de metaloprotease di-hétero substituìdos
HUP0202199A2 (en) 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
EP1041072B1 (en) 1999-03-31 2003-07-16 Pfizer Products Inc. Dioxocyclopentyl hydroxamic acids
ATE309241T1 (de) 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
MXPA02004985A (es) 1999-11-26 2003-10-14 Shionogi & Co Antagonistas del neuropeptido y, y5.
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
WO2001070690A1 (en) * 2000-03-21 2001-09-27 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
IL151250A0 (en) * 2000-03-21 2003-04-10 Procter & Gamble Difluorobutyric acid metalloprotease inhibitors
JP2003528078A (ja) * 2000-03-21 2003-09-24 ザ プロクター アンド ギャンブル カンパニー 炭素環式側鎖を含有するメタロプロテアーゼ阻害剤
KR20020081465A (ko) * 2000-03-21 2002-10-26 더 프록터 앤드 갬블 캄파니 헤테로시클릭 측쇄 함유, ｎ-치환된 메탈로프로테아제저해제
US6495358B1 (en) 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
WO2001092244A1 (en) * 2000-05-30 2001-12-06 Wayne State University Inhibitors of matrix metalloproteinases
US20040235896A1 (en) * 2001-03-14 2004-11-25 Fujimoto Roger Aki Certain azacycloalkyl substituted acetic acid derivatives
WO2002092553A1 (en) * 2001-05-11 2002-11-21 Guilford Pharmaceuticals Inc. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
ES2255621T3 (es) 2001-06-22 2006-07-01 MERCK & CO., INC. Inhibidores de tirosina quinasa.
JP2005507937A (ja) 2001-11-01 2005-03-24 ワイス・ホールディングズ・コーポレイション マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
WO2003104224A1 (en) 2002-06-10 2003-12-18 Pfizer Inc. Metabolites of prinomastat and their sythesis
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
CA2509060A1 (en) * 2002-12-27 2004-07-22 Angiotech International Ag Compositions and methods of using collagen and mmpi
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7576222B2 (en) * 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US7928127B2 (en) 2005-05-19 2011-04-19 Notre Dame University Inhibitors of matrix metallaproteinases
CA2730708A1 (en) * 2008-07-14 2010-01-21 Novartis Ag Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors
US8937151B2 (en) 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
BR112013008008A2 (pt) 2010-09-24 2016-06-21 Ranbaxy Lab Ltd composto, composição farmacêutica e processo para preparar um composto

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077998A (en) * 1975-10-28 1978-03-07 Morton-Norwich Products, Inc. Phthaloyl amino acid hydroxamic acids
US4885027A (en) * 1985-04-05 1989-12-05 Chevron Research Company Herbicidal arylmethylenesulfonamido-acetamide and thioacetamide derivatives
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
EP0320898A3 (en) * 1987-12-18 1989-08-16 Schering Corporation Processes and compounds useful for resolving 1-methyl-3-phenylpropylamine
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
DE69108529T2 (de) * 1990-12-03 1995-11-30 Celltech Therapeutics Ltd Peptidylderivate.
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB2303850B (en) * 1994-06-22 1998-06-10 British Biotech Pharm Metalloproteinase inhibitors
US5817822A (en) * 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
KR20000011095A (ko) * 1996-05-17 2000-02-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 비페닐술폰아미드 매트릭스 메탈로프로테이나아제 억제제

Also Published As

Publication number Publication date
NO965515D0 (no) 1996-12-20
GB2303850A (en) 1997-03-05
EP0766664A2 (en) 1997-04-09
AU2746595A (en) 1996-01-15
GB2303629B (en) 1998-09-02
NZ288298A (en) 1998-12-23
EP0766665B1 (en) 1999-07-28
JPH10507158A (ja) 1998-07-14
DE69511089T2 (de) 1999-12-16
CA2193692A1 (en) 1995-12-28
NO965515L (no) 1997-02-20
DK0766665T3 (da) 1999-12-06
GR3033446T3 (en) 2000-09-29
US6124332A (en) 2000-09-26
EP0766664B1 (en) 2000-04-05
CA2193691A1 (en) 1995-12-28
DE69516143D1 (de) 2000-05-11
CN1151157A (zh) 1997-06-04
DK0766664T3 (da) 2000-07-31
WO1995035275A1 (en) 1995-12-28
ATE182581T1 (de) 1999-08-15
US6124329A (en) 2000-09-26
GB9623809D0 (en) 1997-01-08
PT766664E (pt) 2000-08-31
EP0766665A2 (en) 1997-04-09
US6022898A (en) 2000-02-08
WO1995035276A1 (en) 1995-12-28
AU2746695A (en) 1996-01-15
ATE191468T1 (de) 2000-04-15
ES2145913T3 (es) 2000-07-16
AU690703B2 (en) 1998-04-30
GB2303629A (en) 1997-02-26
GR3031143T3 (en) 1999-12-31
FI965153A0 (fi) 1996-12-20
AU695507B2 (en) 1998-08-13
DE69516143T2 (de) 2000-10-19
GB2303850B (en) 1998-06-10
JPH10501806A (ja) 1998-02-17
NZ288299A (en) 1998-06-26
US5962529A (en) 1999-10-05
GB9623675D0 (en) 1997-01-08
ES2133785T3 (es) 1999-09-16
DE69511089D1 (de) 1999-09-02

Similar Documents

Publication Publication Date Title
ATE182581T1 (de) Metalloproteinase-inhibitoren
SE9402431D0 (sv) New tablet formulation
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
AR023366A1 (es) Uso de benzolactamas n-carboximetil sustituidas para la fabricacion de un medicamento para la inhibicion de las metaloproteinasas de la matriz, paratratamiento de un estado de enfermedad neoplasico, para tratamiento de aterosclerosis, para tratamiento de una enfermedad inflamatoria cronica y paratra
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
ATE253359T1 (de) Antithrombotische mittel
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DE69828522D1 (de) Antithrombotische mittel
FI932654A (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
HUP0203321A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrug készítmények gyulladás kezelésére
ES2194899T3 (es) Composicion farmaceutica para administracion transdermica sistemica del principio activo morfina-6-glucuronido.
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
DE69910787D1 (de) Neuartige, pharmazeutisch aktive verbindung
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
ATE268768T1 (de) Antithrombosemittel
ATE109981T1 (de) Therapeutische mittel.
JO1881B1 (en) Formula II for multi unit disc calibration
IT1255678B (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.